Antibiotic resistance is one of the most serious threats to global public health, and the pipeline of new antibiotics capable of overcoming it has been dangerously thin for decades. Researchers at The Scripps Research Institute have now made a significant advance: they have structurally modified vancomycin, one of medicine’s most reliable last resort antibiotics, to produce a version with three independent mechanisms of action and a 1,000 fold increase in activity. The finding, published in the Proceedings of the National Academy of Sciences, could provide a durable solution against resistant bacterial infections for years to come.
Why Vancomycin Is Central to the Antibiotic Resistance Challenge
Vancomycin has been in clinical use for 60 years, and bacteria are only now beginning to develop meaningful resistance to it. That unusual durability reflects the strength of its original mechanism of action, which works by disrupting the way bacteria construct their cell walls. Dale Boger, co chair of the Department of Chemistry at TSRI and lead researcher on the study, described vancomycin as a near magical starting point for antibiotic development precisely because of its proven track record against serious infections. Previous work by Boger and his colleagues had already demonstrated that two structural modifications to vancomycin could make it significantly more potent, reducing the dose needed to achieve the same therapeutic effect. The new study adds a third modification that interferes with bacterial cell wall formation through an entirely different mechanism, one that is distinct from both the original vancomycin action and the two prior enhancements.
How Triple Mechanism Action Addresses Antibiotic Resistance
The strategic importance of three independent mechanisms of action cannot be overstated in the context of antibiotic resistance. Bacteria evolve resistance by finding ways to neutralize or work around a drug’s mechanism of attack. When a single mechanism is targeted, resistance can develop over time as bacterial populations encounter selective pressure. When three separate and independent mechanisms must all be overcome simultaneously, the probability of resistance emerging drops dramatically. As Boger explained, organisms cannot realistically find solutions to three independent mechanisms of action at the same time. Even if a bacterium managed to develop resistance to one mechanism, the remaining two would continue to be lethal. This multi pronged approach represents a fundamentally different and more durable strategy against antibiotic resistance than developing new single mechanism drugs. In laboratory testing against Enterococci bacteria, including vancomycin resistant Enterococci strains that already pose a serious clinical problem, the modified vancomycin killed both the resistant and original forms of the bacteria. This is particularly significant because vancomycin resistant Enterococci infections are among the most difficult to treat in clinical settings and represent a major driver of hospital acquired mortality.
What Comes Next in Antibiotic Resistance Research
The current synthesis process for the modified vancomycin requires 30 laboratory steps, which represents a practical challenge for large scale production. Boger acknowledged this but characterized it as the comparatively straightforward part of the project relative to the far more difficult work of designing the molecule itself. Efforts are underway to streamline the synthesis process, and Boger expressed confidence that this is achievable. Even if synthesis efficiency is not immediately improved, Boger argued that the importance of the modified vancomycin justifies its production by current methods given the ongoing failure of the antibiotic pipeline to keep pace with the growth of antibiotic resistance. Antibiotics represent total cures for bacterial infections, a category of therapeutic outcome that most other drug classes cannot claim. To read more about infectious disease and antimicrobial research, visit the FOMAT blog. FOMAT conducts infectious disease clinical trials at sites across the United States. To learn more about active studies, visit FOMAT’s patient studies page. For the full source, see the original article at Bioscience Technology.